Remdesivir manufacturing projections 2020

As of July 2020, American biopharmaceutical company Gilead Sciences expected that they will produce more than two million treatment courses of their antiviral drug remdesivir by the end of the year in order to meet the global real-time need. This statistic depicts the cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020.

Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s)

Characteristic	Cumulative treatment courses in thousands
December	2,000
July	288
June	190
April	30
January	5

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

July 2020

More information

Region

United States

Survey time period

as of July 2020

Supplementary notes

Original manufacturing projections from January to May based on 11-vial treatment course. Projections through end of June based on average 7.78 vials per treatment course. Year-end projection based on average 6.25 vials per treatment course.
Figures reflect the cumulative amount of drug that Gilead expects to produce and are inclusive of supply allocated for clinical trials, compassionate use and expanded access programs, and any potential regulatory authorizations or approvals.

Citation formats